Abstract

Preview
Since the publication in 2016 of the recommendations on the appropriate use of albumin in patients with liver cirrhosis endorsed by the Italian Association for the Study of the Liver (AISF) and the Italian Association of Transfusion Medicine and Immunohematology (SIMTI)1,2, a considerable amount of pathophysiological and clinical data have been collected on the long-term administration of human albumin in decompensated cirrhosis. Considering the potential impact of these novel results on daily clinical practice, which will likely lead to an increase in the demand for human albumin, and taking into account the limited availability of this blood product, the two scientific associations nominated a panel of experts to review the available clinical literature and produce new practical clinical recommendations for the long-term use of human albumin in patients with decompensated cirrhosis. [ … ]

Downloads

Authors

Paolo Caraceni - Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy

Paolo Angeli - Department of Medicine, University of Padua, Padua, Italy

Daniele Prati - Department of Transfusion Medicine and Haematology, Fondazione IRCCS Ca’ Granda Ospedale, Maggiore Policlinico, Milan, Italy

Mauro Bernardi - Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; on behalf of the Italian Association for the Study of the Liver (AISF)

Pierluigi Berti - Immunohaematology and Transfusion Service, Aosta, Italy

Francesco Bennardello - Immunohaematology and Transfusion Medicine Centre, Provincial Health Authority, Ragusa, Italy

Francesco Fiorin - Transfusion Service, Vicenza, Italy

Pierluigi Piccoli - Transfusion Medicine Unit, University Hospital of Verona, Verona, Italy; on behalf of the Italian Society of Transfusion Medicine and Immunohaematology (SIMTI)

  • Abstract viewed - 8 times
  • PDF downloaded - 3 times